MedTrace Logo

Autoimmunity in Retinitis Pigmentosa

NCT00433277 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2007-02-09

No results posted yet for this study

Summary

Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.

Conditions

Interventions

DRUG

twice-daily dosage with 0.5% cyclosporine-A eyedrops

Sponsors & Collaborators

  • Semmelweis University

    lead OTHER

Principal Investigators

  • Zoltán Z. Nagy, M.D. · Semmelweis University, Dept. of Ophthalmology

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00433277 on ClinicalTrials.gov